Apnimed, Inc.

What they do

Apnimed is dedicated to the discovery, development and commercialization of novel oral therapies for sleep-related breathing diseases. Its sole clinical product candidate, AD109 (proposed name Oxnimbi), is an investigational fixed-dose anti-apneic neuromuscular modulator combining an anti-muscarinic and a selective norepinephrine reuptake inhibitor, designed to improve upper airway muscle activity during sleep. The company submitted an NDA for Oxnimbi in April 2026, which the FDA accepted for review in July 2026. Apnimed has no approved products and currently generates no product revenue.

Revenue drivers

• Oxnimbi (AD109) — Sole clinical product candidate, not yet approved or commercialized. If approved, it would potentially be the first oral pharmacologic therapy for OSA, but no product revenue has been generated to date.
• SASS disposition proceeds — In April 2026, Apnimed sold its interest in the Shionogi-Apnimed Sleep Science joint venture to Shionogi, receiving a $100.0 million upfront payment and eligibility for a one-time $50.0 million milestone payment.
• Financing activities — The company completed an upsized IPO for gross proceeds of $220.8 million and a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners.

Recent performance

For the second quarter ended June 30, 2026, Apnimed reported revenue of $12.1 million, down from $17.1 million in the same quarter of 2025. As of June 30, 2026, the company had cash and cash equivalents of $172.8 million, total assets of $195.5 million, total liabilities of $125.7 million, and shareholder equity of negative $176.2 million. Long-term debt stood at $40.3 million. The company completed its upsized IPO after quarter-end, with gross proceeds of $220.8 million.

Strategy

Apnimed is focused on advancing Oxnimbi toward potential FDA approval and U.S. commercialization, with a PDUFA target action date of February 28, 2027. The company has strengthened its financial position through an upsized IPO and a senior secured credit facility of up to $150 million to support commercial readiness and a potential U.S. launch. It also monetized its interest in the Shionogi-Apnimed Sleep Science joint venture for $100 million upfront, allowing it to concentrate resources on Oxnimbi. Leadership was transitioned with appointments of Kevin Lind as CEO, Michael Kelly as CFO, and Steven Spector as Chief Legal Officer.

Risks

• Regulatory approval risk — Oxnimbi is Apnimed's only clinical candidate and has not received FDA approval; the NDA is under review with a PDUFA date of February 28, 2027, and the FDA may not approve the product.
• No product revenue — The company has no approved products and generated only $12.1 million in revenue in the most recent quarter, relying on financing and disposition proceeds to fund operations.
• Negative shareholder equity — As of June 30, 2026, Apnimed reported shareholder equity of negative $176.2 million and total liabilities of $125.7 million.
• Clinical trial and commercial execution risk — Even if approved, Oxnimbi faces risks related to commercial launch, market acceptance, and competition in the OSA treatment landscape.

Outlook

Management stated that the FDA's acceptance of the NDA for Oxnimbi with a PDUFA target action date of February 28, 2027, positions the company to potentially launch the first oral pharmacologic therapy for OSA. Apnimed is advancing commercial readiness activities and building capabilities to support a potential U.S. launch, supported by its strengthened financial position from the IPO and credit facility. The company believes Oxnimbi has the potential to address the unmet need in a U.S. OSA population estimated at 80 million people.